DEBRA GIBSON: Open Payments
NPI 1811694482 · MESA, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,257 in 80 payments from 10 companies in 2025. Trend: 2023 $197 · 2024 $1,000 · 2025 $2,257
Food & beverage: $2,255Education: $1
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 32 | $754 |
| Otsuka America Pharmaceutical, Inc. | 14 | $464 |
| Alkermes, Inc. | 12 | $347 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $285 |
| Vanda Pharmaceuticals Inc. | 7 | $191 |
| Janssen Pharmaceuticals, Inc | 4 | $105 |
| Biogen, Inc. | 2 | $56 |
| Braeburn Inc. | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $15 |
Products named: VRAYLAR, ARISTADA, CAPLYTA, ABILIFY MAINTENA, FANAPT, REXULTI, ABILIFY ASIMTUFII, SPRAVATO.
Industry payments across AZ — which companies pay providers there.
